ClinicalTrials.gg
TerminatedNCT05853458HU-F-AIMUpdated Aug 18, 2026

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

A Phase 4 interventional study of Hydroxyurea in Polycythemia Vera, sponsored by Novartis Pharmaceuticals. Terminated at 21 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Polycythemia Vera by Novartis — none open to participants now, 2 under way, none of them phase 3. Polycythemia Vera · Novartis.

Started
2023
with 1 other
Phase 4
2 of 12
none open now
Registered
10th of 12
by date

Among the 12 studies in Polycythemia Vera by Novartis, this one is one of 2 that started in 2023, is one of 2 in phase 4, and was the 10th registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

None of the 12 studies in Polycythemia Vera by Novartis is open now. The open studies under Polycythemia Vera, anywhere →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Polycythemia Vera by Novartis as a file.
02

Study summary

The purpose of this study is to confirm the predictive factors for hydroxyurea (HU) failure (hemoglobin (HGB) \<15.5 g/dL (9.62 mmol/L) and red blood cell distribution width (RDW) ≥17%) identified by machine learning in the polycythemia vera advanced integrated model (PV-AIM) project in the real-life setting.

Read the detailed description

The study consists of three periods: Screening period, treatment period (observation for HU-resistance/intolerance) and follow-up (FU) period.

Eligible participants will enter the treatment period (observation period for HU-resistance/intolerance) and start receiving the de novo HU treatment. The maximum treatment duration for each participant in the study will be up to 15 months.

This study will be conducted in a total of 300 adult PV patients and approximately at 30 to 40 sites in Germany. If necessary, the study will be extended to other countries to achieve the target population.

03

Conditions studied

  • Polycythemia Vera

Browse trials for

Keywords

  • Polycythemia vera (PV)
  • Hydroxyurea
  • Resistance
  • Intolerance
  • Predictive parameters
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria

  1. Signed must be obtained prior to participation in the study
  2. Patients ≥18 years
  3. Confirmed diagnosis of Polycythemia vera (according to WHO 2008, 2016, or 2022 criteria) (Tefferi and Vardiman 2008, Arber et al 2016, Khoury et al 2022)
  4. (ECOG) ≤ 2
  5. No previous pharmacologic cytoreductive therapy (including drugs)
  6. No phlebotomy in last 14 days
  7. HU-eligible

    • High-risk: age ≥ 60 years and/or prior history of thrombosis
    • Low-risk: showing at least one of the defined criteria

      • Signs of disease progression (myeloproliferation):

        • Increase in spleen size or symptomatic splenomegaly
        • increase to > 1,000,000/µl
        • WBC increase to > 15,000/µl or higher
        • Frequent (> 10 per year) or increasing frequency of phlebotomies
      • Increasing risk of thromboembolism and bleeding:

        • New thromboembolism and/or hemorrhagic complications
        • Microcirculation disorders despite acetyl salicylic acid (ASA) 2x 100 mg/day
        • Restricted feasibility or intolerance of phlebotomies
        • Symptomatic iron deficiency
        • Uncontrolled increase in hematocrit
        • Severe or distressing disease-related symptoms
  8. Female participants of should have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study treatment.

Key Exclusion criteria

  1. Patients with post-polycythemia vera myelofibrosis (post-PV MF) or accelerated phase/ blast phase myeloproliferative neoplasm acute myeloid leukemia (AP/BP-MPN AML).
  2. Patients with a to HU according to the SmPC (severe bone marrow depression, leukopenia (\< 2.5 x 109 leukocytes/l), thrombocytopenia (\< 100 x 109 platelets/L), severe anemia (\< 10 g/dL HGB).
  3. Patients with rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption in their past medical history.
  4. Active uncontrolled infection that is considered by the Investigator as a reason for exclusion.
  5. Active (except for carcinoma in situ; prostate cancer and breast cancer in remission and - where necessary - ongoing hormonal therapy).
  6. Inadequate renal function as demonstrated by Modification of Diet in Renal Disease estimate (MDRDeGFR) \< 30 mL/min/1.73m2 or on dialysis.
  7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hCG) laboratory test.
  8. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for at least 3 months after stopping study treatment.
  9. patients treated with nucleoside reverse transcriptase inhibitors like didanosine and stavudine.

Other inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Hydroxyurea (HU)

    Participants will be treated with HU capsules, orally taken, for a maximum duration of 15 months.

    Drug: Hydroxyurea

Interventions

  • Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment

06

What researchers measure

Primary outcomes

  1. Proportion of PV patients with HU-resistance/intolerance within 6-9 months after start of de novo HU- treatment in presence of the PV-AIM HU-resistance predictors at the start of HU treatment.

    Proportion of PV participants with HU resistance/intolerance within 6-9 months after start of de novo HU treatment in presence of the PV-AIM HU resistance predictors at the start of HU treatment. The proportion will be assessed calculating the rate together with the respective 95% confidence interval (CI).

    Time frame: From 6 to 9 months after start of de novo HU-treatment

Secondary outcomes

  1. Proportion of PV patients who meet the PV-AIM HU-resistance predictors before start of HU-treatment

    Proportion of PV patients who meet the PV-AIM HU-resistance predictors before start of HU-treatment. The proportion will be assessed calculating the rate together with the respective 95% confidence interval (CI).

    Time frame: Baseline

  2. Proportion of patients developing HU resistance/intolerance at any time within the maximum treatment period of 15 months

    Proportion of patients developing HU resistance/intolerance at any time within the maximum treatment period of 15 months. The proportion will be assessed calculating the rate together with the respective 95% confidence interval (CI).

    Time frame: Up to 15 months

  3. Proportion of "non-switchers"

    For all patients who develop HU resistance/intolerance according to modified European LeukemiaNet (ELN) criteria at any time during the maximum treatment period of 15 months, the proportion of "non-switchers" (i.e., patients remaining on HU despite they meet the HU-resistance/intolerance criteria) will be assessed. The rate will be calculated together with the respective 95% confidence interval (CI).

    Time frame: Up to 15 months

  4. Timepoint of therapy switch (after confirmation of HU resistance/intolerance)

    For all patients who develop HU resistance/intolerance according to modified ELN criteria at any time during the maximum treatment period of 15 months, the timepoint of therapy switch (after confirmation of HU resistance/intolerance) will be assessed.

    Time frame: Up to 15 months

  5. Reasons for therapy switch / non-switch

    For all patients who develop HU resistance/intolerance according to modified ELN criteria at any time during the maximum treatment period of 15 months, the reasons for therapy switch or non-switch will be summarized

    Time frame: Up to 15 months

  6. Therapies applied during follow-up period

    For all patients who develop HU resistance/intolerance according to modified ELN criteria at any time during the maximum treatment period of 15 months, the therapies applied during the follow-up period will be summarized

    Time frame: Up to 3 months after treatment discontinuation

07

Study locations

21 sites
  • Novartis Investigative Site
    Heidelberg, Baden-Wurttemberg 69115, Germany
  • Novartis Investigative Site
    Kronach, Bavaria 96317, Germany
  • Novartis Investigative Site
    Straubing, Bavaria 94315, Germany
  • Novartis Investigative Site
    Langen, Hesse 63225, Germany
  • Novartis Investigative Site
    Lingen, Lower Saxony 49808, Germany
  • Novartis Investigative Site
    Aachen, North Rhine-Westphalia 52064, Germany
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50674, Germany
  • Novartis Investigative Site
    Dortmund, North Rhine-Westphalia 44309, Germany
  • Novartis Investigative Site
    Velbert, North Rhine-Westphalia 42551, Germany
  • Novartis Investigative Site
    Saarbrücken, Saarland 66113, Germany
  • Novartis Investigative Site
    Merseburg, Saxony-Anhalt 06217, Germany
  • Novartis Investigative Site
    Berlin, 10407, Germany
  • Novartis Investigative Site
    Donauwörth, 86609, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Erding, 85435, Germany
  • Novartis Investigative Site
    Gütersloh, 33332, Germany
  • Novartis Investigative Site
    Hanover, 30161, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Mutlangen, 73557, Germany
  • Novartis Investigative Site
    Naunhof, 04683, Germany
  • Novartis Investigative Site
    Würselen, 52146, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Feb 2026, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
May 10, 2023
StartActual
Jul 28, 2023
Primary completionActual
Feb 26, 2026
CompletionActual
Feb 26, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05853458
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Jul 28, 2023
Primary completion
Feb 26, 2026
Completion
Feb 26, 2026
Last update
Aug 18, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxyurea

Start the discussion